Shankar Vallabhajosula

Company: Convergent Therapeutics, Inc

Job title: VP Radiopharmaceutical Sciences

Seminars:

The Hidden Metric – Why Dosimetry is a Pillar of Radiopharmaceutical Manufacturing & How Integrating it Early Ensures Patient Safety, Product Consistency & Regulatory Confidence 9:30 am

Discover how dosimetry informs production yields and formulation volumes and how this data helps optimize radioactive content per batch and adjust for decay rates during production. Explore how dosimetry requirements influence formulation volume, carrier molecule concentration, and specific activity which drives critical manufacturing decisions from early development through scale-up. Examine the ongoing lack of standardization…Read more

day: Conference Day Two

Follow-up Roundtable: Discussing Why Dosimetry is a Pillar of Radiopharmaceutical Manufacturing & How Integrating it Early Ensures Patient Safety, Product Consistency & Regulatory Confidence 10:00 am

Discussing the practical role of dosimetry in Phase 3 trials and commercial settings. When does it add real value, and when does it become an unnecessary burden? Exploring industry-wide challenges with standardization and how to ensure consistent and reliable dosimetry across trial sites with varying equipment and expertise. Evaluating strategies for improving data quality and…Read more

day: Conference Day Two

Optimizing Isotope Selection for Improved Patient Outcomes, Manufacturing Efficiency & Commercial Benefit: A Scandium-Based Strategy 9:05 am

Selecting the ideal isotope for targeted radiotherapy or imaging requires deep understanding not only of physical properties like radiation type, half-life, and decay chains but also how isotope generation methods impact downstream quality control, and safety. Discover how strategic isotope selection that leverages theragnostic pairing can significantly improve the commercial viability of radiopharmaceuticals. This workshop…Read more

day: Pre-Conference Workshop Day